271 related articles for article (PubMed ID: 10632308)
1. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Nevitt MC; Thompson DE; Black DM; Rubin SR; Ensrud K; Yates AJ; Cummings SR
Arch Intern Med; 2000 Jan; 160(1):77-85. PubMed ID: 10632308
[TBL] [Abstract][Full Text] [Related]
2. The association of radiographically detected vertebral fractures with back pain and function: a prospective study.
Nevitt MC; Ettinger B; Black DM; Stone K; Jamal SA; Ensrud K; Segal M; Genant HK; Cummings SR
Ann Intern Med; 1998 May; 128(10):793-800. PubMed ID: 9599190
[TBL] [Abstract][Full Text] [Related]
3. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
[TBL] [Abstract][Full Text] [Related]
4. Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial.
Cauley JA; Black D; Boonen S; Cummings SR; Mesenbrink P; Palermo L; Man Z; Hadji P; Reid IR;
J Bone Miner Res; 2011 May; 26(5):984-92. PubMed ID: 21542001
[TBL] [Abstract][Full Text] [Related]
5. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
Cummings SR; Black DM; Thompson DE; Applegate WB; Barrett-Connor E; Musliner TA; Palermo L; Prineas R; Rubin SM; Scott JC; Vogt T; Wallace R; Yates AJ; LaCroix AZ
JAMA; 1998 Dec 23-30; 280(24):2077-82. PubMed ID: 9875874
[TBL] [Abstract][Full Text] [Related]
6. Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT).
Fink HA; Ensrud KE; Nelson DB; Kerani RP; Schreiner PJ; Zhao Y; Cummings SR; Nevitt MC
Osteoporos Int; 2003 Jan; 14(1):69-76. PubMed ID: 12577187
[TBL] [Abstract][Full Text] [Related]
7. Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. The Fracture Intervention Trial Research Group.
Nevitt MC; Ross PD; Palermo L; Musliner T; Genant HK; Thompson DE
Bone; 1999 Nov; 25(5):613-9. PubMed ID: 10574584
[TBL] [Abstract][Full Text] [Related]
8. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Black DM; Cummings SR; Karpf DB; Cauley JA; Thompson DE; Nevitt MC; Bauer DC; Genant HK; Haskell WL; Marcus R; Ott SM; Torner JC; Quandt SA; Reiss TF; Ensrud KE
Lancet; 1996 Dec; 348(9041):1535-41. PubMed ID: 8950879
[TBL] [Abstract][Full Text] [Related]
9. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
[TBL] [Abstract][Full Text] [Related]
10. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
[TBL] [Abstract][Full Text] [Related]
11. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
[TBL] [Abstract][Full Text] [Related]
12. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
Ettinger B; Black DM; Mitlak BH; Knickerbocker RK; Nickelsen T; Genant HK; Christiansen C; Delmas PD; Zanchetta JR; Stakkestad J; Glüer CC; Krueger K; Cohen FJ; Eckert S; Ensrud KE; Avioli LV; Lips P; Cummings SR
JAMA; 1999 Aug; 282(7):637-45. PubMed ID: 10517716
[TBL] [Abstract][Full Text] [Related]
13. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study.
Kushida K; Shiraki M; Nakamura T; Kishimoto H; Morii H; Yamamoto K; Kaneda K; Fukunaga M; Inoue T; Nakashima M; Orimo H
J Bone Miner Metab; 2004; 22(5):462-8. PubMed ID: 15316867
[TBL] [Abstract][Full Text] [Related]
14. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial.
Quandt SA; Thompson DE; Schneider DL; Nevitt MC; Black DM;
Mayo Clin Proc; 2005 Mar; 80(3):343-9. PubMed ID: 15757015
[TBL] [Abstract][Full Text] [Related]
15. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Hadji P; Zanchetta JR; Russo L; Recknor CP; Saag KG; McKiernan FE; Silverman SL; Alam J; Burge RT; Krege JH; Lakshmanan MC; Masica DN; Mitlak BH; Stock JL
Osteoporos Int; 2012 Aug; 23(8):2141-50. PubMed ID: 22159672
[TBL] [Abstract][Full Text] [Related]
16. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
17. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
Adachi JD
Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
[TBL] [Abstract][Full Text] [Related]
18. The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis.
Genant HK; Halse J; Briney WG; Xie L; Glass EV; Krege JH
Curr Med Res Opin; 2005 Jul; 21(7):1027-34. PubMed ID: 16004669
[TBL] [Abstract][Full Text] [Related]
19. The antifracture efficacy of alendronate.
Seeman E
Int J Clin Pract Suppl; 1999 Apr; 101():40-5. PubMed ID: 12675021
[TBL] [Abstract][Full Text] [Related]
20. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
Hochberg MC; Ross PD; Black D; Cummings SR; Genant HK; Nevitt MC; Barrett-Connor E; Musliner T; Thompson D
Arthritis Rheum; 1999 Jun; 42(6):1246-54. PubMed ID: 10366118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
